

Eva Forssell-Aronsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6012429/publications.pdf>

Version: 2024-02-01

134
papers

2,658
citations

185998

28
h-index

243296

44
g-index

139
all docs

139
docs citations

139
times ranked

3050
citing authors

#	ARTICLE	IF	CITATIONS
1	Specific Growth Rate versus Doubling Time for Quantitative Characterization of Tumor Growth Rate. <i>Cancer Research</i> , 2007, 67, 3970-3975.	0.4	200
2	Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. <i>Scientific Reports</i> , 2020, 10, 5798.	1.6	106
3	A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake. <i>American Journal of Pathology</i> , 2001, 158, 745-755.	1.9	86
4	A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. <i>Journal of Neural Transmission</i> , 2008, 115, 1051-1062.	1.4	82
5	Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷ Lu-DOTATATE treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 947-955.	3.3	79
6	Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. <i>Journal of Pathology</i> , 2001, 195, 463-472.	2.1	62
7	[¹⁷⁷ Lu-DOTA-Tyr ³]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney. <i>World Journal of Surgery</i> , 2010, 34, 1368-1372.	0.8	62
8	Biodistribution and Dosimetry of Free ²¹¹ At, ¹²⁵ I ^α and ¹³¹ I ^α in Rats. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 657-664.	0.7	62
9	Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 1617-1629.	2.3	57
10	Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. <i>Journal of Nuclear Medicine</i> , 2006, 47, 807-14.	2.8	56
11	Down-regulation of the Sodium/Iodide Symporter Explains ¹³¹ I-Induced Thyroid Stunning. <i>Cancer Research</i> , 2007, 67, 7512-7517.	0.4	53
12	Estimation of absorbed dose to the kidneys in patients after treatment with ¹⁷⁷ Lu-octreotate: comparison between methods based on planar scintigraphy. <i>EJNMMI Research</i> , 2012, 2, 49.	1.1	52
13	Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 514-524.	0.4	46
14	Transcriptional response in normal mouse tissues after i.v. ²¹¹ At administration - response related to absorbed dose, dose rate, and time. <i>EJNMMI Research</i> , 2015, 5, 1.	1.1	46
15	Radiation-Induced Thyroid Stunning: Differential Effects of ¹²³ I, ¹³¹ I, ^{99m} Tc, and ²¹¹ At on Iodide Transport and NIS mRNA Expression in Cultured Thyroid Cells. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1161-1167.	2.8	44
16	Chromogranin A as a determinant of midgut carcinoid tumour volume. <i>Regulatory Peptides</i> , 2004, 120, 269-273.	1.9	43
17	Stunning of iodide transport by (¹³¹ I) irradiation in cultured thyroid epithelial cells. <i>Journal of Nuclear Medicine</i> , 2002, 43, 828-34.	2.8	42
18	Dosimetric characterization of radionuclides for systemic tumor therapy: Influence of particle range, photon emission, and subcellular distribution. <i>Medical Physics</i> , 2006, 33, 3260-3269.	1.6	40

#	ARTICLE	IF	CITATIONS
19	Tumour size measurement in a mouse model using high resolution MRI. <i>BMC Medical Imaging</i> , 2012, 12, 12.	1.4	38
20	Similarities and differences between free ²¹¹ At and ¹²⁵ I ^α transport in porcine thyroid epithelial cells cultured in bicameral chambers. <i>Nuclear Medicine and Biology</i> , 2001, 28, 41-50.	0.3	37
21	Quantitative analysis of tumor growth rate and changes in tumor marker level: Specific growth rate versus doubling time. <i>Acta Oncol³gica</i> , 2009, 48, 591-597.	0.8	35
22	Gastric Carcinoid with Histamine Production, Histamine Transporter and Expression of Somatostatin Receptors. <i>Digestion</i> , 1998, 59, 160-166.	1.2	34
23	Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. <i>Nuclear Medicine and Biology</i> , 2006, 33, 841-846.	0.3	34
24	Nephrotoxicity profiles and threshold dose values for [¹⁷⁷ Lu]-DOTATATE in nude mice. <i>Nuclear Medicine and Biology</i> , 2012, 39, 756-762.	0.3	34
25	NAMPT Inhibitor GMX1778 Enhances the Efficacy of ¹⁷⁷ Lu-DOTATATE Treatment of Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 288-292.	2.8	33
26	Comparison of Electron Dose-Point Kernels in Water Generated by the Monte Carlo Codes, PENELOPE, GEANT4, MCNPX, and ETRAN. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 461-467.	0.7	31
27	Biodistribution data from 100 patients i.v. injected with ¹¹¹ In-DTPA-D-Phe ¹ -Octreotide. <i>Acta Oncol³gica</i> , 2004, 43, 436-442.	0.8	30
28	Transcriptional response of BALB/c mouse thyroids following in vivo astatine-211 exposure reveals distinct gene expression profiles. <i>EJNMMI Research</i> , 2012, 2, 32.	1.1	30
29	Somatostatin Receptor Subtypes, Octreotide Scintigraphy, and Clinical Response to Octreotide Treatment in Patients with Neuroendocrine Tumors. <i>World Journal of Surgery</i> , 1998, 22, 679-683.	0.8	28
30	¹¹⁴ mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-Phe-octreotide. <i>Nuclear Medicine and Biology</i> , 2000, 27, 183-188.	0.3	28
31	Intraoperative tumour detection using ¹¹¹ In-DTPA-D-Phe ¹ -octreotide and a scintillation detector. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1456-1462.	3.3	28
32	Differences in Biodistribution Between ^{99m} Tc-Depreotide, ¹¹¹ In-DTPA-Octreotide, and ¹⁷⁷ Lu-DOTA-Tyr ³ -Octreotate in a Small Cell Lung Cancer Animal Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 231-236.	0.7	28
33	Comparative Analysis of Transcriptional Gene Regulation Indicates Similar Physiologic Response in Mouse Tissues at Low Absorbed Doses from Intravenously Administered ²¹¹ At. <i>Journal of Nuclear Medicine</i> , 2013, 54, 990-998.	2.8	27
34	Radiation therapy of small cell lung cancer with ¹⁷⁷ Lu-DOTA-Tyr ³ -octreotate in an animal model. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1542-8.	2.8	27
35	Biodistribution of Free ²¹¹ At and ¹²⁵ I ^α in Nude Mice Bearing Tumors Derived from Anaplastic Thyroid Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 591-600.	0.7	26
36	Can Quantification of VMAT and SSTR Expression Be Helpful for Planning Radionuclide Therapy of Malignant Pheochromocytomas?. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 491-497.	1.8	24

#	ARTICLE	IF	CITATIONS
37	Effects of internal low-dose irradiation from ¹³¹ I on gene expression in normal tissues in Balb/c mice. EJNMMI Research, 2011, 1, 29.	1.1	24
38	Hedgehog inhibitor sonidegib potentiates ¹⁷⁷ Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer, 2017, 17, 528.	1.1	24
39	Therapy with Radiopharmaceuticals. Acta Oncol ³ gica, 2002, 41, 623-628.	0.8	23
40	Biodistribution of ¹¹¹ In-DTPA-D-Phe ¹ -octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nuclear Medicine and Biology, 2003, 30, 253-260.	0.3	23
41	Importance of Vesicle Proteins in the Diagnosis and Treatment of Neuroendocrine Tumors. Annals of the New York Academy of Sciences, 2004, 1014, 280-283.	1.8	23
42	Model of metastatic growth valuable for radionuclide therapy. Medical Physics, 2003, 30, 3227-3232.	1.6	22
43	Malignant Pheochromocytoma in a Population-Based Study: Survival and Clinical Results. Annals of the New York Academy of Sciences, 2006, 1073, 512-516.	1.8	22
44	Effects of Treatment with ¹⁷⁷ Lu-DOTA-Tyr ³ -Octreotate on Uptake of Subsequent Injection in Carcinoid-Bearing Nude Mice. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 644-653.	0.7	22
45	Comparison of [¹⁷⁷ Lu-DOTA-Tyr ³]-Octreotate and [¹⁷⁷ Lu-DOTA-Tyr ³]-Octreotide for Receptor-Mediated Radiation Therapy of the Xenografted Human Midgut Carcinoid Tumor GOT1. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 114-120.	0.7	22
46	Protection of Kidney Function with Human Antioxidation Protein α -Microglobulin in a Mouse ¹⁷⁷ Lu-DOTATATE Radiation Therapy Model. Antioxidants and Redox Signaling, 2019, 30, 1746-1759.	2.5	22
47	Effects of k-space filtering and image interpolation on image fidelity in 1H MRSI. Magnetic Resonance Imaging, 2001, 19, 1227-1234.	1.0	20
48	Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies. Neuroendocrinology, 2013, 97, 86-98.	1.2	20
49	Time- and dose rate-related effects of internal ¹⁷⁷ Lu exposure on gene expression in mouse kidney tissue. Nuclear Medicine and Biology, 2014, 41, 825-832.	0.3	19
50	Dose-specific transcriptional responses in thyroid tissue in mice after ¹³¹ I administration. Nuclear Medicine and Biology, 2015, 42, 263-268.	0.3	19
51	Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma. Oncotarget, 2018, 9, 24140-24154.	0.8	19
52	Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from ¹³¹ I in vitro. Journal of Nuclear Medicine, 2007, 48, 481-6.	2.8	19
53	Medical Imaging for Improved Tumour Characterization, Delineation and Treatment Verification. Acta Oncol ³ gica, 2002, 41, 604-614.	0.8	18
54	Radiation Therapy Through Activation of Stable Nuclides. Acta Oncol ³ gica, 2002, 41, 629-634.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Biodistribution of ¹⁷⁷ Lu-octreotate and ¹¹¹ In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2. <i>Oncology Reports</i> , 2011, 27, 174-81.	1.2	17
56	Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs. <i>Acta Oncol</i> , 2013, 52, 783-792.	0.8	16
57	Priming increases the anti-tumor effect and therapeutic window of ¹⁷⁷ Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1. <i>EJNMMI Research</i> , 2017, 7, 6.	1.1	16
58	GOT1 Xenografted to Nude Mice: A Unique Model for <i>In Vivo</i> Studies on SSTR-Mediated Radiation Therapy of Carcinoid Tumors. <i>Annals of the New York Academy of Sciences</i> , 2004, 1014, 275-279.	1.8	15
59	Radiation Induces Up-Regulation of Somatostatin Receptors 1, 2, and 5 in Small Cell Lung Cancer <i>In Vitro</i> Also at Low Absorbed Doses. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 759-765.	0.7	15
60	Extended ISIS sequences insensitive to T1 smearing. <i>Magnetic Resonance in Medicine</i> , 2000, 44, 546-555.	1.9	14
61	Transcriptional response of kidney tissue after ¹⁷⁷ Lu-octreotate administration in mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, 238-247.	0.3	14
62	Clonal relatedness in tumour pairs of breast cancer patients. <i>Breast Cancer Research</i> , 2018, 20, 96.	2.2	14
63	¹⁷⁷ Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. <i>Endocrine-Related Cancer</i> , 2019, 26, 437-449.	1.6	14
64	Modelling of metastatic cure after radionuclide therapy: Influence of tumor distribution, cross-irradiation, and variable activity concentration. <i>Medical Physics</i> , 2004, 31, 2628-2635.	1.6	13
65	Gene expression signature in mouse thyroid tissue after ¹³¹ I and ²¹¹ At exposure. <i>EJNMMI Research</i> , 2015, 5, 59.	1.1	13
66	Signal profile measurements for evaluation of the volume-selection performance of ISIS. <i>NMR in Biomedicine</i> , 1995, 8, 271-277.	1.6	12
67	Adsorption and volatility of free ²¹¹ At and ¹²⁵ I. <i>Applied Radiation and Isotopes</i> , 2019, 151, 108757. <small>xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.elsevier.com/xml/ja/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:tbl_struct="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:ce="http://www.elsevier.com/xml/common/citation-element/dtd"</small>	0.7	12
68	A new method to estimate parameters of the growth model for metastatic tumours. <i>Theoretical Biology and Medical Modelling</i> , 2013, 10, 31.	2.1	12
69	Circadian rhythm influences genome-wide transcriptional responses to ¹³¹ I in a tissue-specific manner in mice. <i>EJNMMI Research</i> , 2015, 5, 75.	1.1	12
70	Transcriptional Response in Mouse Thyroid Tissue after ²¹¹ At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration. <i>PLoS ONE</i> , 2015, 10, e0131686.	1.1	12
71	Multiparametric MR for non-invasive evaluation of tumour tissue histological characteristics after radionuclide therapy. <i>NMR in Biomedicine</i> , 2019, 32, e4060.	1.6	12
72	Potential Biomarkers for Radiation-Induced Renal Toxicity following ¹⁷⁷ Lu-Octreotate Administration in Mice. <i>PLoS ONE</i> , 2015, 10, e0136204.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Tumour control probability (TCP) for non-uniform activity distribution in radionuclide therapy. <i>Physics in Medicine and Biology</i> , 2008, 53, 4369-4381.	1.6	10
74	Microarray Studies on ²¹¹ At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Nonthyroid Tissues. <i>Journal of Nuclear Medicine</i> , 2017, 58, 346-353.	2.8	10
75	Transcriptional response to ¹³¹ I exposure of rat thyroid gland. <i>PLoS ONE</i> , 2017, 12, e0171797.	1.1	10
76	Analysis of inter-patient variations in tumour growth rate. <i>Theoretical Biology and Medical Modelling</i> , 2014, 11, 21.	2.1	9
77	Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to ¹⁷⁷ Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. <i>Translational Oncology</i> , 2018, 11, 193-204.	1.7	9
78	Biokinetics of ¹¹¹ In-DTPA-D-Phe ¹ -octreotide in nude mice transplanted with a human carcinoid tumor. <i>Nuclear Medicine and Biology</i> , 2001, 28, 67-73.	0.3	8
79	New Medical Strategies for Midgut Carcinoids. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 250-269.	0.9	8
80	Microdosimetric analysis of ²¹¹ At in thyroid models for man, rat and mouse. <i>EJNMMI Research</i> , 2012, 2, 29.	1.1	8
81	Dosimetric analysis of ¹²³ I, ¹²⁵ I and ¹³¹ I in thyroid follicle models. <i>EJNMMI Research</i> , 2014, 4, 23.	1.1	8
82	Linking loss of sodium-iodide symporter expression to DNA damage. <i>Experimental Cell Research</i> , 2016, 344, 120-131.	1.2	8
83	¹ H magnetic resonance spectroscopy evidence for occipital involvement in treatment-naïve paediatric obsessive-compulsive disorder. <i>Acta Neuropsychiatrica</i> , 2017, 29, 179-190.	1.0	8
84	Effects of different mean arterial pressure targets on plasma volume, ANP and glycocalyx: A randomized trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 220-227.	0.7	8
85	Signal profile measurements of single- and double-volume acquisitions with image-selected in vivo spectroscopy for ³¹ P magnetic resonance spectroscopy. <i>Magnetic Resonance Imaging</i> , 1998, 16, 829-837.	1.0	7
86	Performance of 2D ¹ H spectroscopic imaging of the brain: some practical considerations regarding the measurement procedure. <i>Magnetic Resonance Imaging</i> , 1999, 17, 919-931.	1.0	7
87	Transport of free ²¹¹ At and ¹²⁵ I ⁻ in thyroid epithelial cells: effects of anion channel blocker 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid on apical efflux and cellular retention. <i>Nuclear Medicine and Biology</i> , 2007, 34, 523-530.	0.3	7
88	Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after ¹⁷⁷ Lu-DOTA-Tyr ³ -octreotate treatment: a histological study in xenografted mice. <i>EJNMMI Research</i> , 2011, 1, 19.	1.1	7
89	Non-targeted transcriptomic effects upon thyroid irradiation: similarity between in-field and out-of-field responses varies with tissue type. <i>Scientific Reports</i> , 2016, 6, 30738.	1.6	7
90	The amount of injected ¹⁷⁷ Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice. <i>Acta Oncologica</i> , 2016, 55, 68-76.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after ¹⁷⁷ Lu[Lu]-octreotate therapy. <i>Nuclear Medicine and Biology</i> , 2018, 60, 11-18.	0.3	7
92	Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer. <i>PLoS ONE</i> , 2019, 14, e0225260.	1.1	7
93	Genetic alterations associated with multiple primary malignancies. <i>Cancer Medicine</i> , 2021, 10, 4465-4477.	1.3	7
94	Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose ¹³¹ I exposure. <i>PLoS ONE</i> , 2020, 15, e0244098.	1.1	7
95	Aspects on Radionuclide Therapy in Malignant Pheochromocytomas. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 498-504.	1.8	6
96	Translation of Dosimetric Results of Preclinical Radionuclide Therapy to Clinical Situations: Influence of Photon Irradiation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 268-274.	0.7	6
97	Advances in the diagnostic imaging of pheochromocytomas. <i>Reports in Medical Imaging</i> , 2011, , 19.	0.8	6
98	Inhomogeneous activity distribution of ¹⁷⁷ Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice. <i>Tumor Biology</i> , 2012, 33, 229-239.	0.8	6
99	Deconvolution of expression microarray data reveals ¹³¹ I-induced responses otherwise undetected in thyroid tissue. <i>PLoS ONE</i> , 2018, 13, e0197911.	1.1	5
100	Data-driven identification of tumor subregions based on intravoxel incoherent motion reveals association with proliferative activity. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 1480-1490.	1.9	5
101	Genomic profiling of the transcription factor Zfp148 and its impact on the p53 pathway. <i>Scientific Reports</i> , 2020, 10, 14156.	1.6	5
102	Distinct microRNA Expression Profiles in Mouse Renal Cortical Tissue after ¹⁷⁷ Lu-octreotate Administration. <i>PLoS ONE</i> , 2014, 9, e112645.	1.1	5
103	Therapy with radiopharmaceuticals. <i>Acta Oncologica</i> , 2002, 41, 623-8.	0.8	5
104	Anterior to posterior hippocampal MRS metabolite difference is mainly a partial volume effect. <i>Acta Radiologica</i> , 2010, 51, 351-359.	0.5	4
105	Neuroblastoma xenograft models demonstrate the therapeutic potential of ¹⁷⁷ Lu-octreotate. <i>BMC Cancer</i> , 2021, 21, 950.	1.1	4
106	Age and sex effects across the blood proteome after ionizing radiation exposure can bias biomarker screening and risk assessment. <i>Scientific Reports</i> , 2022, 12, 7000.	1.6	4
107	The magnitude of signal errors introduced by ISIS in quantitative ³¹ P MRS. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2002, 14, 30-38.	1.1	3
108	Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with ¹⁷⁷ Lu-octreotate. <i>EJNMMI Research</i> , 2014, 4, 59.	1.1	3

#	ARTICLE	IF	CITATIONS
109	Transcriptional effects of ¹⁷⁷ Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice. <i>EJNMMI Research</i> , 2019, 9, 28.	1.1	3
110	The magnitude of signal errors introduced by ISIS in quantitative ³¹ P MRS. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2002, 14, 30-8.	1.1	2
111	The influence of cardiac triggering time and an optimization strategy for improved cardiac MR spectroscopy. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 310-317.	0.6	2
112	Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors. <i>PLoS ONE</i> , 2020, 15, e0233720.	1.1	2
113	Neurochemical properties measured by ¹ H magnetic resonance spectroscopy may predict cognitive behaviour therapy outcome in paediatric OCD: a pilot study. <i>Journal of Neural Transmission</i> , 2021, 128, 1361-1370.	1.4	2
114	Medical imaging for improved tumour characterization, delineation and treatment verification. <i>Acta Oncol</i> , 2002, 41, 604-14.	0.8	2
115	Radiation therapy through activation of stable nuclides. <i>Acta Oncol</i> , 2002, 41, 629-34.	0.8	2
116	Radiolanthanides in nuclear medicine. <i>Metal Ions in Biological Systems</i> , 2004, 42, 77-108.	0.4	2
117	A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1619-1628.	1.1	1
118	Evaluation of two intraoperative gamma detectors for assessment of ¹⁷⁷ Lu activity concentration in vivo. <i>EJNMMI Physics</i> , 2017, 4, 3.	1.3	1
119	Estimation of tumour volume at therapy initiation by back-extrapolating the post-therapy regression curve of tumour volume. <i>Applied Cancer Research</i> , 2018, 38, .	1.0	1
120	The IRI-DICE hypothesis: ionizing radiation-induced DSBs may have a functional role for non-deterministic responses at low doses. <i>Radiation and Environmental Biophysics</i> , 2020, 59, 349-355.	0.6	1
121	Hyperfractionated Treatment with ¹⁷⁷ Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model. <i>Cancers</i> , 2022, 14, 235.	1.7	1
122	Natural radioactivity and element characterization in pit lakes in Northern Sweden. <i>PLoS ONE</i> , 2022, 17, e0266002.	1.1	1
123	A transplantable human carcinoid as model for somatostatin receptor- and amine transporter mediated radionuclide uptake. <i>Gastroenterology</i> , 2000, 118, A520.	0.6	0
124	A Novel Photon Radiation Detector System for In Vitro Biokinetic Measurements. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 629-638.	0.7	0
125	[OA166] A1M is a potential kidney protector in ¹⁷⁷ Lu-octreotate treatment of neuroendocrine tumours. <i>Physica Medica</i> , 2018, 52, 63-64.	0.4	0
126	[OA164] Vandetanib may act as a radiosensitiser for ¹⁷⁷ Lu-octreotate treatment of medullary thyroid cancer. <i>Physica Medica</i> , 2018, 52, 62-63.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Local treatment of liver metastases by administration of ¹⁷⁷ Lu-octreotate via isolated hepatic perfusion – A preclinical simulation of a novel treatment strategy. <i>Surgical Oncology</i> , 2019, 29, 148-156.	0.8	0
128	VERDICT MRI for radiation treatment response assessment in neuroendocrine tumors. <i>NMR in Biomedicine</i> , 2021, , e4680.	1.6	0
129	Age-related long-term response in rat thyroid tissue and plasma after internal low dose exposure to ¹³¹ I. <i>Scientific Reports</i> , 2022, 12, 2107.	1.6	0
130	Swedish Cancer Society radiation therapy research investigation. <i>Acta Oncologica</i> , 2002, 41, 596-603.	0.8	0
131	Title is missing!. , 2020, 15, e0233720.		0
132	Title is missing!. , 2020, 15, e0233720.		0
133	Title is missing!. , 2020, 15, e0233720.		0
134	Title is missing!. , 2020, 15, e0233720.		0